Current Situation of Health Care in Women With HBV or HCV Infection
NCT ID: NCT06579313
Last Updated: 2024-08-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
2500 participants
OBSERVATIONAL
2024-09-01
2025-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study on Gut Microbiota in Chronic HBV Infected Patients
NCT03587467
Long-Term Study of Liver Disease in People With Hepatitis B and/or Hepatitis C With or Without HIV Infection
NCT01350648
A Comprehensive HBsAg-positive Patients Centered Screening Strategy
NCT03794791
Prevalence of Occult Hepatitis B Virus Infection(OBI) in Subjects With Chronic Hepatitis B(CHB) Family History
NCT04672915
The Follow-up Study of Chronic Hepatitis B Patients With Liver Cirrhosis Receiving Anti-HBV Therapy
NCT01957618
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
So far, data on the current health care status in HBV-infected women is scarce. With the expansion of treatment indications recommended by China CHB guidelines, more female patients will have the opportunity to gain timely and necessary treatment. This study will analyze the cascade of care by observing the duration from diagnosis to treatment and treatment adherence for women. And this knowledge will serve as a guide for interventions for the management of viral hepatitis, as well as effectively finding and activating patients who meet treatment criteria but are not being treated.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HBV cohort
2000 HBsAg positive patients during 2016.7-2019.12
No interventions assigned to this group
HCV cohort
500 HCV Ab positive and HCV RNA positive patients during 2020.7-2023.12
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ≥18 years old
* serum HBsAg positive for \>6 months
* Treatment naïve or,
* Patients who had been previously treated for HBV but discontinued for at least 1 year before enrollment
HCV Cohort -
* ≥18 years old
* HCV-Ab positive
* HCV RNA positive
* Treatment naïve or,
* Patients who had been previously treated for HCV with a regimen containing interferon and not had a sustained virologic response.
Exclusion Criteria
* HIV
* History of hepatic decompensation or hepatocellular carcinoma
* Other carcinoma
* Other severe liver disease
* Severe Comorbidity like cardiovascular disease, diabetes etc.
* Patients who had discontinued previous HCV treatment because of an adverse event.
* Patients who had previously received any nucleotide analogue HCV NS5B inhibitor or any NS5A inhibitor
* Patients who had discontinued previous HBV treatment because of an adverse event.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ruijin Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Qing Xie
Role: PRINCIPAL_INVESTIGATOR
Ruijin Hospital
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IN-US-987-7219
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.